John Lykouretzos, founder and CIO of Hoplite Capital Management, said he was bullish for footwear apparel company Nike (NKE)  , particularly because of the profit it is making — and he expects will continue to make — from its e-commerce and retail business.

"This dynamic is being under appreciated by investors. I think Nike is a really attractive long," Lykouretzos said. "I think Nike will continue to accelerate and take share from others."

Nike traded recently at $52 a share.

And Kynikos Associates' James Chanos, famous for his shorting campaign at Enron, on Thursday presented a short case at Mallinckrodt (MNK)  .

Chanos focused on Mallinckrodt's Acthar drug, which he argued will represent a large amount of its operating income. He argued Mallinckrodt was a very levered company and he pointed to a Federal Trade Commission ruling in January requiring Mallinckrodt to license a generic competitor to Acthar for infantile spasms.

"The bulls think this will continue to grow and it will continue to raise prices on what is already probably the most egregiously overpriced drug in the U.S.," Chanos said.

Chanos urged lawmakers on Capitol Hill, including Sen. Claire McCaskill, D-Missouri, to investigate what he called a "murky" alliance between Mallinckrodt and Express Scripts   (ESRX)  .

"The business model itself is questionable," he said.

Chanos has short positions in MNK and ESRX.

It was unclear whether the thesis was viable without government intervention. However, Chanos suggested his shorting campaign could work even without any action by lawmakers, adding that if Mallinckrodt's revenue drops a little bit it could result in slashed profits because of the company's debt.

"What kind of economic play would you give Acthar, even if nothing happens in four years?" he said. "I can say that in 10 years we can pretty much count on Acthar being replaced by generics or negotiated down." 

Chanos's picks don't always work out, however. Last year at SALT, Chanos launched a shorting campaign at Cheniere Energy   (LNG)  , calling it "financial engineering gone crazy." Cheniere's shares traded at about $34.05 a share at the time, but have since risen to trade at about $48.72 a share Thursday afternoon.

Mallinckrodt did not return a request for comment.

More from Investing

Jim Cramer: What Has to Happen for These Stocks to Be in Favor Again?

Jim Cramer: What Has to Happen for These Stocks to Be in Favor Again?

Heat Biologics Takes Beating After Pricing $12 Million Stock Offering

Heat Biologics Takes Beating After Pricing $12 Million Stock Offering

Foot Locker's Jumping High on International and Internet-Driven Growth

Foot Locker's Jumping High on International and Internet-Driven Growth

Facebook's Zuckerberg Says He's Not Going Anywhere, Sticks by Sandberg

Facebook's Zuckerberg Says He's Not Going Anywhere, Sticks by Sandberg

Market Conditions Were Good for a Little Holiday Spirit

Market Conditions Were Good for a Little Holiday Spirit